Towards individualized, low toxic conditioning in autologous gene-transduced hematopoietic cell transplantation
Published: November 18, 2019Clinical Trial Designs For Advanced Therapies
Rick Admiraal, Susan Prockop & Jaap Jan Boelens
Allogeneic hematopoietic cell transplantation (Allo-HCT) has become much safer over the last couple of years. This, together with the rapidly evolving autologous HCT-gene therapy options, is expected to result in an increase in the number of patients receiving HCT. Autologous HCT-gene therapy is a more advanced, safer and precise option for monogenetic life threatening disorders. The efficacy of gene therapy, however, does not only rely on the gene construct itself, but also on the conditioning applied before the gene therapy. In this review we describe how the conditioning can impact the outcomes of the allo-HCT and gene therapy and we will provide a future perspective on how to further improve the efficacy and reduce the short- and long-term toxicity of the conditioning.
DOI: 10.18609/cgti.2019.155Submitted for review: October 2, 2019
Citation: Cell & Gene Therapy Insights 2019; 5(11), 1495-1503.
